Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report) and...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)

Analysts are intrested in these 5 stocks: ( ($AQN) ), ( ($SPOT) ), ( ($KEYS) ), ( ($NTLA) ) and ( ($CRWV) ). Here is a breakdown of their recent


Algonquin, Spotify, Keysight, Intellia, CoreWeave: Trending by Analysts

Intellia Therapeutics received a Hold rating and price target from Evercore ISI analyst Jonathan Miller yesterday. The company’s shares closed yest...

Intellia Therapeutics (NTLA) was downgraded to a Hold Rating at Evercore ISI

Intellia Therapeutics ( ($NTLA) ) has provided an update. On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 ...

Intellia Reports Favorable Phase 1 Data for Nex-Z

In a report released yesterday, Brian Cheng from J.P. Morgan downgraded Intellia Therapeutics to a Sell, with a price target of $5.00. The company’...

J.P. Morgan downgrades Intellia Therapeutics (NTLA) to a Sell

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Friday, November 7, according to daily fund dis...

Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat

Intellia Therapeutics Inc (($NTLA)) has held its Q3 earnings call. Read on for the main highlights of the call. Intellia Therapeutics Inc. recently...

Intellia Therapeutics’ Earnings Call: Progress Amid Challenges

In a report released on November 1, Myles Minter from William Blair maintained a Hold rating on Intellia Therapeutics. The company’s shares closed ...

William Blair Remains a Hold on Intellia Therapeutics (NTLA)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Friday, October 31, 2025, continuing their recent tr...

Cathie Wood Cuts Stake in Palantir Stock (PLTR) Ahead of Q3, Loads Up on Bullish (BLSH) and Intellia (NTLA)

Analysts are intrested in these 5 stocks: ( ($DASH) ), ( ($MSFT) ), ( ($NTLA) ), ( ($UPWK) ) and ( ($QRVO) ). Here is a breakdown of their recent


DoorDash, Microsoft, Intellia, Upwork, Qorvo: Trending by Analysts

Intellia Therapeutics ( ($NTLA) ) has shared an update. On October 29, 2025, Intellia Therapeutics was informed by the FDA of a clinical hold on th...

Intellia Therapeutics Faces FDA Clinical Hold on Trials

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several notable portfolio moves for Tuesday, October 28, 2025, showing continued con...

Cathie Wood Boosts Biotech Bets, Cuts Back on Tech Favorites, Including Shopify and Palantir (PLTR)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Intellia Therapeutics. The company’s shares opened today at $...

Intellia Therapeutics (NTLA) Receives a Rating Update from a Top Analyst

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Intellia Therapeutics, with a price target of $54.00...

Canaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Monday, October 27, 2025, signaling stronger convict...

AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks

The latest update is out from Intellia Therapeutics ( ($NTLA) ). On October 27, 2025, Intellia Therapeutics announced a temporary pause in dosing a...

Intellia Therapeutics Pauses Phase 3 Trials Due to Safety Concerns

Intellia Therapeutics Inc (($NTLA)) announced an update on their ongoing clinical study. Intellia Therapeutics Inc. is conducting a study titled ‘L...

Intellia’s NTLA-2002: A Promising Long-Term Study Update

Intellia Therapeutics stock dove on Monday alongside an update to a Phase 3 clinical trial.


Market Cap	$981.08M	P/E Ratio	N/A
52W High	$28.25	52W Low	$5.90
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	0.0%	52W Position	10.3%
Overall Score	38	Value Score	60
Quality Score	--	Technical Score	16

EPS Current Est	$-4	EPS Next Est	$-3.61
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NTLA	$8.21	+2.11%	6.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NTLA	$8.21	+2.1%	6.25M
3
4
5
6

NTLA

NTLA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Intellia Therapeutics Inc. Data in Excel

Get Intellia Therapeutics Inc. Data in Excel